NLS Clinical Trials

Evaxion has presented new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.

BioArctic's partner Eisai has presented new data at the 2026 Alzheimer’s Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer’s disease.

FluoGuide has announced positive results from the first part of its ongoing FG001-CT-005 Phase 2 trial evaluating FG001 for surgical guidance in patients with oral head and neck cancer.

Elicera Therapeutics held a scientific advice meeting with the Swedish Medical Products Agency (MPA) regarding the planned first-in-human clinical study of ELC-401, the company’s iTANK-armed CAR T-cell candidate targeting IL13Ra2 in grade IV glioma.

Cantargia has reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and therefore at risk of developing lung cancer.

Immunovia has announced new performance data for PancreaSure in support of its upcoming Medicare coverage application.